Sinais e sintomas de cardiotoxicidade nos pacientes oncológicos
revisão de escopo
DOI:
https://doi.org/10.35699/2316-9389.2024.40679Palavras-chave:
Antineoplásicos, Cardiotoxicidade, Neoplasias, Oncologia, Sinais e SintomasResumo
Objetivo: mapear os sinais e sintomas de pacientes adultos submetidos à terapia antineoplásica cardiotóxica. Método: revisão de escopo de acordo com a metodologia do Instituto Joana Briggs. A busca foi realizada nas bases Medline/PubMed, LILACS/BVS, Cochrane Library/Wiley, CINAHL e SCOPUS em dezembro de 2021. Os estudos foram gerenciados pelo Endnote e selecionados no Rayyan, de acordo com os critérios de elegibilidade. Resultados: foram identificados 297 estudos e destes, 25 foram incluídos na revisão. Foram mapeados sinais e sintomas de danos cardiovasculares diretos e indiretos, associados a alterações estruturais, funcionais e isquêmicas. Conclusão: os sinais e sintomas mais frequentemente citados nos estudos foram dor torácica, diminuição da fração de ejeção, insuficiência cardíaca, arritmias e dispneia. O mapeamento apresentado neste estudo pode contribuir para o reconhecimento precoce desses sinais e sintomas, direcionando a prática em saúde.
Downloads
Referências
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2019[citado em 2022 jun. 30]. 120 p. Disponível em: https://www.inca.gov.br/estimativa
Guha A, Armanious M, Fradley MG. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med [Internet]. 2019[citado em 2022 jun. 30];29(1):29–39. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S1050173818300860
Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol [Internet]. 2019 [citado em 2022 jun. 30];280:163–75. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0167527318358601
Hameau R, Gabrielli L, Garrido M, Guzmán AM, Retamal I, Vacarezza MJ, et al. Cardiotoxicidad inducida por tratamientos oncológicos. Fundamentos para la implementación de equipos de Cardio-Oncología. Rev Méd Chile [Internet]. 2018[citado em 2022 jun. 30];146(1):68–77. Disponível em: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000100068&lng=en&nrm=iso&tlng=en
Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2019 [citado em 2022 jun. 30];139(21). Disponível em: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000679
Peters M, Godfrey C, McInerney P, Munn Z, Trico A, Khalil H. Chapter 11: Scoping Reviews. In: Aromataris E, Munn Z, organizadores. JBI Manual for Evidence Synthesis. 2020[citado em 2022 jun. 30]. Disponível em: https://wiki.jbi.global/display/MANUAL/Chapter+11%3A+Scoping+reviews
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med [Internet]. 2018[citado em 2022 jun. 30];169(7):467–73. Disponível em: https://www.acpjournals.org/doi/10.7326/M18-0850
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg [Internet]. 2010[citado em 2022 jun. 30];8(5):336–41. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S1743919110000403
Tjionas H, Gupta AK. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients. J Oncol Pharm Pract [Internet]. 2017[citado em 2022 jun. 30];23(2):152–6. Disponível em: http://journals.sagepub.com/doi/10.1177/1078155215626788
Grazziotin L, Picon P. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer. J Oncol Pharm Pract [Internet]. 2017[citado em 2022 jun. 30];23(4):264–72. Disponível em: http://journals.sagepub.com/doi/10.1177/1078155216639755
Liu X, Zhu Y, Lin X, Fang L, Yan X. Mitral regurgitation after anthracycline-based chemotherapy in an adult patient with breast cancer: a case report. Medicine (Baltimore) [Internet]. 2017[citado em 2022 jun. 30];96(49):e9004. Disponível em: https://journals.lww.com/00005792-201712080-00068
Watanabe H, Ichihara E, Kano H, Ninomiya K, Tanimoto M, Kiura K. Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). Intern Med [Internet]. 2017[citado em 2022 jun. 30];56(16):2195–7. Disponível em: https://www.jstage.jst.go.jp/article/internalmedicine/56/16/56_8344-16/_article
Lampropoulos S, Roditis P, Koulouris E, Zafiris A, Tzimou M, Kyratlidis K, et al. Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine. Anticancer Drugs [Internet]. 2017[citado em 2022 jun. 30];28(7):801–7. Disponível em: http://journals.lww.com/00001813-201708000-00012
Kwakman JJM, Simkens LHJ, Mol L, Kok WEM, Koopman M, Punt CJA. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer [Internet]. 2017[citado em 2022 jun. 30];76:93–9. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0959804917307347
Polk A, Shahmarvand N, Vistisen K, Vaage-Nilsen M, Larsen FO, Schou M, et al. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open [Internet]. 2016 [citado em 2022 jun. 30];6(10):e012798. Disponível em: https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2016-012798
Van Keerberghen CA, Van Wambeke S, Wolter P, Schöffski P, Van Cleemput J, Van Limbergen E, et al. A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation Therapy. Clin Genitourin Cancer [Internet]. 2017[citado em 2022 jun. 30];15(1):e155–8. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S1558767316301410
Alici H, Balakan O, Ercan S, Cakici M, Yavuz F, Davutoglu V. Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer. Anadolu Kardiyol Derg Anatol J Cardiol [Internet]. 2015[citado em 2022 jun. 30];15(1):56–60. Disponível em: https://www.anatoljcardiol.com//en/evaluation-of-early-subclinical-cardiotoxicity-of-chemotherapy-in-breast-cancer-13535
Jordan JH, D’Agostino RB, Hamilton CA, Vasu S, Hall ME, Kitzman DW, et al. Longitudinal Assessment of Concurrent Changes in Left Ventricular Ejection Fraction and Left Ventricular Myocardial Tissue Characteristics After Administration of Cardiotoxic Chemotherapies Using T1-Weighted and T2-Weighted Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging [Internet]. 2014[citado em 2022 jun. 30];7(6):872–9. Disponível em: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.114.002217
Khan MF, Gottesman S, Boyella R, Juneman E. Gemcitabine-induced cardiomyopathy: a case report and review of the literature. J Med Case Reports [Internet]. 2014[citado em 2022 jun. 30];8(1):220. Disponível em: https://jmedicalcasereports.biomedcentral.com/articles/10.1186/1752-1947-8-220
Y-Hassan S, Tornvall P, Törnerud M, Henareh L. Capecitabine caused cardiogenic shock through induction of global takotsubo syndrome. Cardiovasc Revasc Med [Internet]. 2013 [citado em 2022 jun. 30];14(1):57–61. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S155383891200231X
Kim SM, Kwak CH, Lee B, Kim SB, Sir JJ, Cho WH, et al. A Case of Severe Coronary Spasm Associated with 5-Fluorouracil Chemotherapy. Korean J Intern Med [Internet]. 2012 [citado em 2022 jun. 30];27(3):342. Disponível em: http://kjim.org/journal/view.php?doi=10.3904/kjim.2012.27.3.342
Lestuzzi C, Crivellari D, Rigo F, Viel E, Meneguzzo N. Capecitabine cardiac toxicity presenting as effort angina: a case report. J Cardiovasc Med [Internet]. 2010[citado em 2022 jun. 30];11(9):700–3. Disponível em: https://journals.lww.com/01244665-201009000-00012
Farina A, Malafronte C, Valsecchi MA, Achilli F. Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report. J Cardiovasc Med [Internet]. 2009 [citado em 2022 jun. 30];10(9):722–6. Disponível em: https://journals.lww.com/01244665-200909000-00010
Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol [Internet]. 2008[citado em 2022 jun. 30];26(32):5204–12. Disponível em: https://ascopubs.org/doi/10.1200/JCO.2007.15.6331
Luján J, García de Burgos F, Jordán A, García M, Reyes F, Espinosa MD. Angina en relación con 5-fluorouracilo. Rev Esp Cardiol [Internet]. 2002[citado em 2022 jun. 30];55(7):764–7. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0300893202766967
Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, et al. Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity. Acta Haematol [Internet]. 2000[citado em 2022 jun. 30];104(4):158–63. Disponível em: https://www.karger.com/Article/FullText/46508
Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy [Internet]. 1997[citado em 2022 jun. 30];17(4):729–36. Disponível em: https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1997.tb03748.x?sid=nlm%3Apubmed
Keefe DL, Roistacher N, Pierri MK. Clinical Cardiotoxicity of 5-Fluorouracil. J Clin Pharmacol [Internet]. 1993[citado em 2022 jun. 30];33(11):1060–70. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/j.1552-4604.1993.tb01943.x
Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol [Internet]. 1988 [citado em 2022 jun. 30];13(1):41–6. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/0167814088902964
Landys K, Borgstrom S, Andersson T, Noppa H. Mitoxantrone as a first-line treatment of advanced breast cancer. Invest New Drugs [Internet]. 1985[citado em 2022 jun. 30];3(2). Disponível em: http://link.springer.com/10.1007/BF00174160
Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, Guinan P. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Urology [Internet]. 1985[citado em 2022 jun. 30];26(2):117–24. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/0090429585900421
Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, et al. Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients. Eur J Cancer Clin Oncol [Internet]. 1984[citado em 2022 jun. 30];20(9):1141–6. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/0277537984901226
Lahtinen R, Uusitupa M, Kuikka J, Länsimies E. Non-invasive Evaluation of Anthracycline-induced Cardiotoxicity in Man. Acta Med Scand [Internet]. 2009 [citado em 2022 jun. 30];212(4):201–6. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/j.0954-6820.1982.tb03201.x
Hajjar LA, Costa IBSS, Lopes MACQ, Hoff PMG, Diz MDPE, Fonseca SMR, et al. Diretriz Brasileira de Cardio-oncologia – 2020. Arq Bras Cardiol [Internet]. 2020[citado em 2022 jun. 30];115(5):1006–43. Disponível em: http://abccardiol.org/article/diretriz-brasileira-de-cardio-oncologia-2020/
Hajjar LA, Kalil FR, Hoff PGM. Manual de condutas em cardio-oncologia. Rio de Janeiro: Atheneu; 2018.
Meattini I, Guenzi M, Fozza A, Vidali C, Rovea P, Meacci F, et al. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer. Breast Cancer [Internet]. 2017 [citado em 2022 jun. 30];24(1):52–62. Disponível em: http://link.springer.com/10.1007/s12282-016-0694-3
Osataphan N, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Effects of doxorubicin‐induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: insights for future interventions. J Cell Mol Med [Internet]. 2020[citado em 2022 jun. 30];24(12):6534–57. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.15305
Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of Troponins I and T and N -Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol [Internet]. 2017[citado em 2022 jun. 30];35(8):878–84. Disponível em: https://ascopubs.org/doi/10.1200/JCO.2015.65.7916
Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J [Internet]. 2019[citado em 2022 jun. 30];40(22):1756–63. Disponível em: https://academic.oup.com/eurheartj/article/40/22/1756/5066804
Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J [Internet]. 2019[citado em 2022 jun. 30];40(48):3898–900. Disponível em: https://academic.oup.com/eurheartj/article/40/48/3898/5637731
Arquivos adicionais
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 REME-Revista Mineira de Enfermagem
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Links
Facebook
Instagram
Twitter
